Q-Med AB and Oceana Therapeutics enter into agreements for worldwide rights to Hospital Healthcare Products
Q-Med AB and Oceana Therapeutics, LLC., based in the US, have announced entering into agreements to license worldwide commercialization rights to Deflux® and Solesta™. The agreements also include future products that utilize Q-Med’s proprietary NASHA™ technology.As part of the transaction Oceana Therapeutics is acquiring Q-Med Scandinavia, Inc., which accounts for the majority of the business for Deflux and Solesta. Included in this transaction are the exclusive rights to market, sell and distribute Deflux and Solesta and other products intended for the management of urological and